Author

M. Van Ghelue

Associated professor, UiT - The Artic University of Norway - Cited by 630 - Rheumatology

Biography

Dr. M. Van Ghelue is a Researcher in the department of Bone and Joint research group, Department of Health Science, Medical School, University of Tromsø, Norway. His study A man in his sixties with acute back pain and increasing weakness in his lower limbs. Currently , Dr. Wang is the author/editors/reviewer in several international journals. He published 22 articles in many journals and the articles are informative and got good citations.
Title
Cited by
Year
Levels of transforming growth factor-β are low in systemic lupus erythematosus patients with active disease
A Becker-Merok, GØ Eilertsen, JC NossentThe Journal of rheumatology 37 (10), 2039-2045, 2010201
98
2010
Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus
GØ Eilertsen, C Nikolaisen, A Becker-Merok, JC NossentLupus 20 (6), 607-613, 2011201
79
2011
Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics: a case–control study
GØ Eilertsen, M Van Ghelue, H Strand, JC NossentRheumatology 50 (12), 2197-2205, 2011201
68
2011
The influence of the 1997 updated classification criteria for systemic lupus erythematosus: epidemiology, disease presentation, and patient management
GØ Eilertsen, A Becker-Merok, JC NossentThe Journal of rheumatology 36 (3), 552-559, 2009200
53
2009
Low diagnostic and predictive value of anti-dsDNA antibodies in unselected patients with recent onset of rheumatic symptoms: results from a long-term follow-up Scandinavian …
M Compagno, S Jacobsen, OP Rekvig, L Truedsson, NH Heegaard, ...Scandinavian journal of rheumatology 42 (4), 311-316, 2013201
35
2013
IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role
W Raymond, G Ostli-Eilertsen, S Griffiths, J NossentEuropean journal of rheumatology 4 (1), 29, 2017201
34
2017
Clinical phenotype associations with various types of anti-dsDNA antibodies in patients with recent onset of rheumatic symptoms. Results from a multicentre observational study
M Compagno, OP Rekvig, AA Bengtsson, G Sturfelt, NHH Heegaard, ...Lupus science & medicine 1 (1), e000007, 2014201
34
2014
Association of Achieving Lupus Low Disease Activity State Fifty Percent of the Time With Both Reduced Damage Accrual and Mortality in Patients With Systemic Lupus Erythematosus
C Sharma, WD Raymond, GØ Eilertsen, J NossentWiley, 2019201
33
2019
Mesenchymal stem cells and T cells in the formation of Tertiary Lymphoid Structures in Lupus Nephritis
SE Dorraji, AMK Hovd, P Kanapathippillai, G Bakland, GØ Eilertsen, ...Scientific reports 8 (1), 1-16, 2018201
30
2018
Lupus nephritis: low urinary DNase I levels reflect loss of renal DNase I and may be utilized as a biomarker of disease progression
HL Pedersen, KD Horvei, D Thiyagarajan, GE Norby, N Seredkina, ...The Journal of Pathology: Clinical Research 4 (3), 193-203, 2018201
21
2018
Decreased incidence of lupus nephritis in northern Norway is linked to increased use of antihypertensive and anticoagulant therapy
GØ Eilertsen, S Fismen, TA Hanssen, JC NossentNephrology Dialysis Transplantation 26 (2), 6-627, 111
20
2011
Increased von Willebrand factor levels in patients with systemic lupus erythematosus reflect inflammation rather than increased propensity for platelet activation
JC Nossent, WD Raymond, GØ EilertsenLupus science & medicine 3 (1), e000162, 2016201
19
2016
Hypocomplementemia as a risk factor for organ damage accrual in patients with systemic lupus erythematosus
W Raymond, G Eilertsen, J NossentJournal of immunology research 20, 202
18
2018
Principal component analysis reveals disconnect between regulatory cytokines and disease activity in Systemic Lupus Erythematosus
WD Raymond, GØ Eilertsen, J NossentCytokine 114, 67-73, 2019201
17
2019
Achieving Lupus Low Disease Activity State (LLDAS‐50) is associated with both reduced damage accrual and mortality in patients with Systemic Lupus Erythematosus
C Sharma, W Raymond, G Eilertsen, J NossentArthritis care & research, 2019201
16
2019
APRIL levels strongly correlate with IL-17 in systemic lupus erythematosus
GØ Eilertsen, JC NossentLupus 23 (13), 1383-1391, 2014201
16
2014
The Impact of Cytokines on the Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus
WD Raymond, GØ Eilertsen, S Shanmugakumar, JC NossentJournal of clinical medicine 8 (6), 857, 2019201
10
2019
Insulin-like growth factor-1 (IGF1) in systemic lupus erythematosus: relation to disease activity, organ damage and immunological findings
J Waldron, W Raymond, G Ostli-Eilertsen, J NossentLupus 27 (6), 63-70, 2018201
9
2018
Erythroleukaemia complicating ANA‐negative systemic lupus erythematosus
GØ Eilertsen, JC NossentScandinavian journal of rheumatology 36 (6), 48-480, 20020
7
2007
The assessment of serum-mediated phagocytosis of necrotic material by polymorphonuclear leukocytes to diagnose and predict the clinical features of systemic lupus erythematosus …
M Compagno, B Gullstrand, S Jacobsen, GØ Eilertsen, JÅ Nilsson, ...Arthritis research & therapy 18 (1), 44, 2016201
5
2016

Referred From: https://scholar.google.com/citations?user=buNEK_YAAAAJ&hl=no

Cited by
Citations 630
h-index 16
i10-index 17
Open Access Journals